Gene helps predict which ovarian cancer sufferers will benefit most from chemotherapy

September 19, 2012
Gene helps predict which women with ovarian cancer will benefit most from chemotherapy

(Medical Xpress)—Researchers from the University of Dundee have discovered that measuring how active a gene is could predict which women with ovarian cancer will benefit from platinum-based chemotherapy drugs - a common treatment for the disease.

The team, based at the University's School of Medicine, have found that a gene called FGF1 is highly active in aggressive, advanced ovarian cancers, and it is found at higher levels in cancer cells that are resistant to platinum chemotherapy treatments, such as and .

As a result, women with high levels of FGF1 are less likely to respond to these drugs and have a poorer prognosis. The research, funded by Cancer Research UK and the Scottish Funding Council, is published online in the on Wednesday, September 19.

The researchers also found that FGF1 activity increases after ovarian cancer cells become drug resistant. By blocking FGF1 in resistant to platinum drugs, the scientists were able to make them sensitive to chemotherapy again.

Dr Gillian Smith, one of the researchers involved in the study, said, "We're excited by these results because they identify potential ways that ovarian cancer builds resistance to common over time.

"Our study paves the way for the development of new tests to determine if chemotherapy will work and suggests that drugs targeting FGF1 could be effective new treatments for a group of women with a type of ovarian cancer that is difficult to treat successfully."

The researchers measured amounts of a variety of genes in 187 ovarian cancer patients and found each cancer had a unique range of active genes. But, FGF1 appeared to playing the greatest role in determining how cancers behave.

The FGF1 gene encourages cancers to grow a , helping to fuel the tumour's growth.

Dr Julie Sharp, senior science information manager at Cancer Research UK, said, "Ovarian cancer is frequently diagnosed at an advanced stage where surgery is difficult and the disease has spread.

"The current approaches to treatment are limited - not all women respond to chemotherapy and there is no way of telling who will benefit most. This research is a step towards addressing the urgent need to develop tests that can tell us more about each woman's and help personalise treatment to save more lives."

Explore further: Evolving ovarian cancer cells 'dodge' treatment with chemotherapy

More information: Smith G., et al  Individuality in FGF1 expression significantly influences platinum resistance and progression free survival in ovarian cancer (2012) British Journal of Cancer.

Related Stories

Role of known cancer gene in ovarian cancer investigated

February 14, 2012

The role of a known cancer-causing gene in the development of the most lethal type of ovarian cancer is being investigated by researchers from the Walter and Eliza Hall Institute after they were awarded a Cure Cancer Australia ...

Recommended for you

Study: Colonoscopy after 75 may not be worth it

September 26, 2016

(HealthDay)—A colonoscopy can find and remove cancerous growths in the colon, but it may not provide much cancer prevention benefit after the age of 75, a new study suggests.

Research finds talc doesn't cause cancer; juries disagree

September 26, 2016

Two lawsuits ended in jury verdicts worth $127 million. Two others were tossed out by a judge who said there wasn't reliable evidence that the talc in Johnson & Johnson's iconic baby powder causes ovarian cancer. So who's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.